Concepedia

Shanthakumar Tyavanagimatt

ST

Statistics

Publications

18

Citations

1.1K

H-Index

17

Active since

2008

Affiliations

Siga Technologies (United States)(Current)

INC Research (United States)

CTI BioPharma (United States)

Fred Hutch Cancer Center

Cleveland Clinic

Shanthakumar Tyavanagimatt is an author at Siga Technologies (United States) specializing in pharmacology, antiviral pharmacology, and antiviral therapy.

ORCID

Publications per year

2008–2023

18

Publications

18

A Novel Inhibitor of Dengue Virus Replication That Targets the Capsid Protein

Chelsea M. Byrd, Dongcheng Dai, Douglas W. Grosenbach et al. · Antimicrobial Agents and Chemotherapy · 2012 · 164 citations · Full text

, , +17

ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose Justification

Robert Jordan, Arthur J. Goff, Annie Frimm et al. · Antimicrobial Agents and Chemotherapy · 2009 · 136 citations · Full text

, , +17

Development of ST-246® for Treatment of Poxvirus Infections

Robert Jordan, Janet M. Leeds, Shanthakumar Tyavanagimatt et al. · Viruses · 2010 · 119 citations · Full text

, , +16

Novel Benzoxazole Inhibitor of Dengue Virus Replication That Targets the NS3 Helicase

Chelsea M. Byrd, Douglas W. Grosenbach, Aklile Berhanu et al. · Antimicrobial Agents and Chemotherapy · 2013 · 112 citations · Full text

, , +17

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

Aaron T. Gerds, Michael R. Savona, Bart L. Scott et al. · Blood Advances · 2020 · 87 citations · Full text

, , +12

1–5 of 18